HanchorBio Inc (TPEx:7827), a Taiwan-based global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, announced on Friday that it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.

Through access to Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard via the Bloomberg Terminal, HanchorBio gains insights into science, strategy and markets, supporting its understanding of biopharma innovation, competitive landscapes, partnerships, and global biotech trends across public and private companies.

HanchorBio says that it views the use of Bloomberg data and research content as part of a broader effort to support decision-making across the drug development lifecycle -- from scientific design and clinical development to regulatory execution, external portfolio, and market strategy.

By combining scientific, development, and strategic insight, HanchorBio aims to strengthen its ability to identify opportunities, evaluate risk, and advance differentiated therapies in the global biopharmaceutical landscape.